CA2678409A1 - Vecteurs viraux recombinants pour la prevention et la protection contre une infection a alphavirus - Google Patents

Vecteurs viraux recombinants pour la prevention et la protection contre une infection a alphavirus Download PDF

Info

Publication number
CA2678409A1
CA2678409A1 CA002678409A CA2678409A CA2678409A1 CA 2678409 A1 CA2678409 A1 CA 2678409A1 CA 002678409 A CA002678409 A CA 002678409A CA 2678409 A CA2678409 A CA 2678409A CA 2678409 A1 CA2678409 A1 CA 2678409A1
Authority
CA
Canada
Prior art keywords
animal
weev
alphaviruses
mice
dna sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002678409A
Other languages
English (en)
Inventor
Leslie P. Nagata
Josh Qiaohua Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minister of National Defence of Canada
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2678409A1 publication Critical patent/CA2678409A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002678409A 2007-02-23 2008-02-22 Vecteurs viraux recombinants pour la prevention et la protection contre une infection a alphavirus Abandoned CA2678409A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90295707P 2007-02-23 2007-02-23
US60/902,957 2007-02-23
PCT/CA2008/000343 WO2008101349A1 (fr) 2007-02-23 2008-02-22 Vecteurs viraux recombinants pour la prévention et la protection contre une infection à alphavirus

Publications (1)

Publication Number Publication Date
CA2678409A1 true CA2678409A1 (fr) 2008-08-28

Family

ID=39709595

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002678409A Abandoned CA2678409A1 (fr) 2007-02-23 2008-02-22 Vecteurs viraux recombinants pour la prevention et la protection contre une infection a alphavirus

Country Status (6)

Country Link
US (2) US8303947B2 (fr)
EP (2) EP2626078A1 (fr)
CA (1) CA2678409A1 (fr)
DK (1) DK2114459T3 (fr)
ES (1) ES2439954T3 (fr)
WO (1) WO2008101349A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764759A1 (fr) 2009-06-09 2010-12-16 Defyrus, Inc. Administration d'interferon pour une prophylaxie contre une infection pathogene ou un traitement d'une infection pathogene
CN101967186B (zh) * 2010-10-09 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 一种脑炎病毒蛋白及其编码基因与应用
CN103014063B (zh) * 2010-10-09 2014-03-05 中国人民解放军军事医学科学院微生物流行病研究所 脑炎病毒蛋白及其一种编码基因与应用
CN103045630B (zh) * 2010-10-09 2014-03-05 中国人民解放军军事医学科学院微生物流行病研究所 脑炎病毒蛋白及其编码基因和应用
CN101967185B (zh) * 2010-10-09 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 脑炎病毒蛋白及其编码基因与应用
PL3407910T3 (pl) 2016-01-29 2022-08-16 Bavarian Nordic A/S Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5831062A (en) 1996-05-09 1998-11-03 Amgen Inc. Use of the human interferon consensus gene for gene therapy
ZA979295B (en) * 1996-10-18 1998-04-20 Canji Inc Methods and compositions for delivery and expression of interferon-Ó nucleic acids.
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
US6261570B1 (en) 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
PT1023442E (pt) * 1997-10-16 2011-02-25 Synageva Biopharma Corp Vectores compreendendo um promotor específico do magno para transgénese aviária
AU2948599A (en) * 1998-03-27 1999-10-18 Secretary Of State For Defence, The Recombinant virus
GB2337755B (en) * 1998-05-29 2003-10-29 Secr Defence Virus vaccine
ES2300261T3 (es) * 1999-04-08 2008-06-16 Novartis Vaccines And Diagnostics, Inc. Potenciacion de la respuesta inmune para aplicaciones de vacunas y terapia genetica.
US20060024270A1 (en) 2000-08-23 2006-02-02 The New York Hospital Medical Center Of Queens Compositions and methods for preventing or treating encephalitis with interferon
US6800289B2 (en) * 2000-12-21 2004-10-05 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Strain of the western equine encephalitis virus
US6812329B2 (en) 2001-02-27 2004-11-02 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Construction and characterization of monoclonal antibodies against western equine encephalitis virus
AU2003224650A1 (en) * 2002-03-02 2003-09-16 University Of South Florida A method for treating allergic disease and asthma by recombinant adenovirus-and adeno-associated virus-mediated ifn-gamma gene
US20060147466A1 (en) 2002-05-14 2006-07-06 Chiron Srl Mucosal combination vaccines for bacterial meningitis
AU2003299962A1 (en) * 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2006088481A2 (fr) * 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Virus de la grippe equine genetiquement modifie et utilisations associees

Also Published As

Publication number Publication date
US20100047274A1 (en) 2010-02-25
US20130058971A1 (en) 2013-03-07
EP2114459A1 (fr) 2009-11-11
EP2626078A1 (fr) 2013-08-14
EP2114459A4 (fr) 2010-05-19
WO2008101349A1 (fr) 2008-08-28
ES2439954T3 (es) 2014-01-27
EP2114459B1 (fr) 2013-09-25
DK2114459T3 (da) 2014-01-13
US8303947B2 (en) 2012-11-06

Similar Documents

Publication Publication Date Title
US20220305111A1 (en) Immunobiological agent for inducing specific immunity against severe acute respiratory syndrome virus sars-cov-2
Atkins et al. Therapeutic and prophylactic applications of alphavirus vectors
JP6639412B2 (ja) アルブミン結合部分を含んでなるアデノウイルス
Ramsburg et al. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals
EP2486137B1 (fr) Vecteurs viraux dérivés du sérotype ad11p compétents pour la réplication
Fooks et al. High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model
US20130058971A1 (en) Innoculation of recombinant viral vectors for rapid pre-exposure prevention and post-exposure protection against alphavirus-induced encephalitides
HU230364B1 (hu) Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
Bharadwaj et al. Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune responses in BALB/c mice
EA026504B1 (ru) Вакцина против rsv
IL207167A (en) Alpha recombinant viruses are attenuated without the ability to replicate mosquitoes and their uses
JP7319368B2 (ja) アデノウイルスおよびアデノウイルスを使用するための方法
JP2017515509A (ja) ワクチン用途のための高力価ウイルス様ベシクルの進化の方法
WO2024056106A1 (fr) Vecteur de virus de la stomatite vésiculaire segmentée, son procédé de préparation et son utilisation
Wu et al. Complete protection of mice against a lethal dose challenge of western equine encephalitis virus after immunization with an adenovirus-vectored vaccine
US20070275873A1 (en) Methods and Compositions Comprising Protein L Immunoglobulin Binding Domains for Cell-Specific Targeting
Wu et al. Pre-and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha
Wang et al. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses
Swayze et al. Envelope protein E1 as vaccine target for western equine encephalitis virus
Zheng et al. Immunogenicity and protective efficacy of Semliki forest virus replicon-based DNA vaccines encoding goatpox virus structural proteins
JP7520008B2 (ja) Ｖｓｖキメラベクター
JP2013048597A (ja) 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するＤＩｓ株由来組換えワクシニアウイルス
Chavda et al. Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. Vaccines 2023, 11, 432
WO2024008014A1 (fr) Composition pharmaceutique pour résister à une infection par le sars-cov-2 ou un mutant de celui-ci et médicament combiné associé
WO2007102140A2 (fr) Vecteur à compétence de réplication du virus forêt semliki à biosécurité améliorée

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130225

FZDE Discontinued

Effective date: 20170906